GXE Stock Chart & Stats
€24.74
-€0.54(-1.96%)
At close: 4:00 PM EST
€24.74
-€0.54(-1.96%)
Day’s Range― - ―
52-Week Range€22.32 - €32.24
Previous CloseN/A
Volume150.00
Average Volume (3M)296.00
Market Cap
€1.76B
Enterprise Value-€394.90
Total Cash (Recent Filing)€2.98B
Total Debt (Recent Filing)€6.43M
Price to Earnings (P/E)3.5
Beta0.40
Next Earnings
Nov 12, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.39
Shares Outstanding65,897,070
10 Day Avg. Volume619
30 Day Avg. Volume296
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.95Price Target Upside0.85% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-2.53
Revenue Forecast (FY)€27.87M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage gives Galapagos substantial financial resilience and flexibility to fund research, partnerships, or restructuring without depending heavily on external borrowing.
Improved ProfitabilityThe shift from prior losses to strong TTM profitability indicates improved earnings power and provides a stronger operating foundation, although sustaining these results remains important.
High Gross MarginsConsistently high gross margins suggest a favorable revenue mix and strong economics on recognized revenue, which can support durable profitability if the company maintains product and partnership quality.
Bears Say
Persistent Cash BurnNegative operating and free cash flow in every reported period means the business is not currently self-funding. Continued cash consumption could reduce financial flexibility despite the strong balance sheet.
Uneven Revenue MomentumThe recent revenue decline following a sharp prior increase points to an unpredictable top-line trajectory, making it harder to assess the durability of growth and future operating leverage.
Earnings VolatilityThe history of significant earnings swings indicates that current profitability may be sensitive to product mix, milestones, or other irregular items, creating uncertainty around sustainable returns.
Lakefront Biotherapeutics NV News
GXE FAQ
What was Lakefront Biotherapeutics NV’s price range in the past 12 months?
Lakefront Biotherapeutics NV lowest stock price was €22.32 and its highest was €32.24 in the past 12 months.
What is Lakefront Biotherapeutics NV’s market cap?
Lakefront Biotherapeutics NV’s market cap is €1.76B.
When is Lakefront Biotherapeutics NV’s upcoming earnings report date?
Lakefront Biotherapeutics NV’s upcoming earnings report date is Nov 12, 2026 which is in 47 days.
How were Lakefront Biotherapeutics NV’s earnings last quarter?
Lakefront Biotherapeutics NV released its earnings results on Aug 10, 2026. The company reported €0.03 earnings per share for the quarter, beating the consensus estimate of -€0.7 by €0.73.
Is Lakefront Biotherapeutics NV overvalued?
According to Wall Street analysts Lakefront Biotherapeutics NV’s price is currently Undervalued.
Does Lakefront Biotherapeutics NV pay dividends?
Lakefront Biotherapeutics NV does not currently pay dividends.
What is Lakefront Biotherapeutics NV’s EPS estimate?
Lakefront Biotherapeutics NV’s EPS estimate is -0.72.
How many shares outstanding does Lakefront Biotherapeutics NV have?
Lakefront Biotherapeutics NV has 65,897,070 shares outstanding.
What happened to Lakefront Biotherapeutics NV’s price movement after its last earnings report?
Lakefront Biotherapeutics NV reported an EPS of €0.03 in its last earnings report, beating expectations of -€0.7. Following the earnings report the stock price went up 4.284%.
Which hedge fund is a major shareholder of Lakefront Biotherapeutics NV?
Currently, no hedge funds are holding shares in DE:GXE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
GXE Stock 12 Month Forecast
Average Price Target
€24.95
▲(0.85% Upside)